ARL-16556
- Generic Name
- ARL-16556
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
- Conditions
- Diffuse Midline Glioma, H3 K27M-MutantDiffuse Intrinsic Pontine Glioma
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Oblato, Inc.
- Registration Number
- NCT05518838
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Arkansas Children's Research Institute, Little Rock, Arkansas, United States
🇺🇸Arnold Palmer Hospital for Children, Orlando, Florida, United States
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
- Conditions
- Brain GlioblastomaRecurrent Malignant Glioma
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04388475
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Lifespan Office of Research, Providence, Rhode Island, United States
🇺🇸The University of Toledo, Toledo, Ohio, United States
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Oblato, Inc.
- Registration Number
- NCT03649464
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 27
- Registration Number
- NCT03587038
- Locations
- 🇺🇸
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
- Conditions
- Hearing LossSensorineural Hearing LossNoise-Induced Hearing Loss
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Otologic Pharmaceutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02259595
- Locations
- 🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01672463
- Locations
- 🇺🇸
Oklahoma University, Oklahoma City, Oklahoma, United States
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
- Conditions
- Cerebral StrokeIschemic Attack, Transient
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT00119626
- Locations
- 🇬🇧
Research Site, Glasgow, United Kingdom
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
- Conditions
- Intracerebral Hemorrhage
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00075959
- Locations
- 🇺🇸
Research Site, Marshfield, Wisconsin, United States
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
- Conditions
- Cerebral StrokeStroke, AcuteCerebrovascular StrokeIschemic Attack, Transient
- First Posted Date
- 2003-05-21
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3200
- Registration Number
- NCT00061022
- Locations
- 🇬🇧
Research Site, Newcastle-upon-Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.